Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 13/20 | 0.53 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025648 | 0.89 | CNR1 (0.56) | ALPLCNR1CCKARLMNA | |
| SCHEMBL6807596 | 0.86 | CNR1 (0.71) | ALPLCNR1 | |
| SCHEMBL6025796 | 0.85 | CNR1 (0.58) | ALPLCNR1CCKARALDH1A1LMNA | |
| SCHEMBL6025823 | 0.85 | CNR1 (0.56) | CNR1CCKAR | |
| SCHEMBL6026092 | 0.85 | CNR1 (0.56) | ALPLCNR1CCKARALDH1A1KDM4E | |
| SCHEMBL6812212 | 0.83 | SLC6A7 (0.55) | CNR1CCKARKDM4ELMNAMAPT | |
| SCHEMBL6025222 | 0.82 | CNR1 (0.52) | CNR1CCKAR | |
| SCHEMBL6025602 | 0.81 | CNR1 (0.53) | CNR1CCKAR | |
| SCHEMBL6025879 | 0.81 | HSD17B10 (0.59) | CNR1CCKARALDH1A1KDM4ELMNA | |
| SCHEMBL6808083 | 0.81 | CNR1 (0.49) | CNR1CCKARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| EP-1638570-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004110453-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ALPL 3252/4885CNR1 1/4885CCKAR 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.